nach oben

Clinical Pharmacokinetics

Erschienen in:

01.12.2001 | Original Research Article

The Influence of Age and Gender on the Pharmacokinetics of Moxifloxacin

verfasst von: John T. Sullivan, John T. Lettieri, Patrick Liu, Allen H. Heller, Dr Susan J. Watson

Erschienen in: Clinical Pharmacokinetics | Sonderheft 1/2001

Einloggen, um Zugang zu erhalten

Abstract

Objective

Moxifloxacin is a new 8-methoxyfluoroquinolone with a broad antibacterial spectrum. The purpose of the present study was to determine the effects of age and gender on pharmacokinetics, surrogate pharmacodynamics, safety and tolerability of a single dose of moxifloxacin.

Design

This was a randomised, double-blind, placebo-controlled, parallel-group single dose trial in young and elderly healthy volunteers.

Patients and participants

The study included 36 volunteers in 3 age and gender groups: young males (mean age 32 years), elderly males (mean age 74 years), and elderly females (mean age 74 years).

Methods

Participants received either a single 200mg oral dose of moxifloxacin (8/group) or placebo (4/group). Blood samples for moxifloxacin pharmacokinetics were obtained before and up to 48 hours after administration. Urine samples were collected for pharmacokinetics, and volunteers were monitored for clinical adverse events and laboratory abnormalities.

Results

Maximum plasma concentration (C_max) and area under the plasma concentration-time curve (AUC) were higher in elderly females than in elderly males; however, when normalised for bodyweight, these pharmacokinetic parameters were not significantly different between the groups. Moreover, the plasma pharmacokinetics in elderly males were not meaningfully different from those in young males. Elimination half-life averaged 12 to 13 hours for the 3 groups. Surrogate pharmacodynamic measures were derived using AUC/MIC (minimal inhibitory concentration) and C_max/MIC ratios. These assessments indicated that, given the linear pharmacokinetics of moxifloxacin previously demonstrated, a dose of 400mg would produce mean C_max/MIC values in the different subgroups ranging from 10.4 to 15.4 for an MIC of 0.25, and 20.8 to 30.8 for an MIC of 0.125. The corresponding ranges of projected AUC/MIC ratios would be 112 to 158 for an MIC of 0.25, and 224 to 314 for an MIC of 0.125. The accepted target values of AUC/MIC and C_max/MIC for quinolones are 125 and 10, respectively. There were no serious adverse events or differences in adverse event profiles between the groups.

Conclusions

Moxifloxacin does not exhibit age- or gender-dependent pharmacokinetics. Oral doses of 200 to 400mg yield effective antibacterial concentrations on the first day of administration.

Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410–25CrossRef

BAY 12-8039: investigator’ brochure. West Haven (CT): Bayer Corporation, Feb 1997

Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997; 41: 1594–7CrossRef

Sullivan JT, Kubitza D, Schühly U, et al. Safety of the new quinolone BAY 12-8039 in 130 healthy volunteers [abstract no. 3355]; 20th International Congress on Chemotherapy. 1997 Jun 29–Jul 3; Sydney, Australia: 108

Stass HH, Dalhoff A, Kubitza D, et al. Bay 12-8039, a new 8-methoxyquinolone: first pharmacokinetic results in healthy male volunteers [abstract no. F024]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisian: 104

Stass HH, Kubitza D, Schwietert R, et al. BAY 12-8039 does not interact with theophylline. 20th International Congress on Chemotherapy [abstract no. 3356]; 1997 Jun 29–Jul 3; Sydney, Australia: 108

Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74CrossRef

Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc., 1982

Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous Ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–81CrossRef

10.

Sullivan MC, Cooper BW, Nightingale CH, et al. Evaluation of the efficacy of Ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemother 1993; 37: 234–9CrossRef

11.

Food-effect bioavailability and bioequivalence studies. Draft Guidance for Industry. Bethesda (MD): US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Dec 1997

12.

Kubitza D, Nagelschmitz J, Wingender W. Investigation of safety, tolerability, and pharmacokinetics of BAY 12-8039 in 6 healthy male volunteers after a single oral dose of 200mg (tablets) [internal report]. Germany: Bayer AG, 1996. Study No.: BAY 12-8039/101

13.

Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. New Engl J Med 1982; 306: 1081–8CrossRef

14.

Stass H, Schühly U, Wingender W Pharmacokinetics, safety, and tolerability of 600 mg BAY 12-8039 administered once daily over 10 days [abstract no. P387]. 8thEuropean Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland. Clin Microbiol Infection 1997; 3 Suppl. 2: 87

15.

Stass H, Kubitza D, Schühly U, et al. Pharmacokinetics, safety, and tolerability of 800 mg BAY 12-8039 administered orally as a single dose [abstract no. P388]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland. Clin Microbiol Infection 1997; 3 Suppl. 2: 87

16.

Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060–5CrossRef

Titel: The Influence of Age and Gender on the Pharmacokinetics of Moxifloxacin
verfasst von: John T. Sullivan
John T. Lettieri
Patrick Liu
Allen H. Heller
Dr Susan J. Watson
Publikationsdatum: 01.12.2001
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe Sonderheft 1/2001
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200140001-00002

Springer Medizin

Abstract

Objective

Design

Patients and participants

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2001

Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration

Effects of Dairy Products on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers

Effect of Probenecid on the Kinetics of a Single Oral 400mg Dose of Moxifloxacin in Healthy Male Volunteers

Lack of Pharmacokinetic Interaction between Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, and Theophylline

Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers

Effect of Calcium Supplements on the Oral Bioavailability of Moxifloxacin in Healthy Male Volunteers